Drug interactions and pharmacokinetics

Drug interactions and pharmacokinetics features

• 

  One in five Kenyan patients suffers major interactions between HIV drugs and other medicines

  Nearly 20% of patients in an HV treatment programme in Kenya have suffered major interactions between their HIV drugs and other prescribed medicines, a study...

  From:  HIV & AIDS treatment in practice

Drug interactions and pharmacokinetics news from aidsmap

• Concentrations of HIV protease inhibitors increase with age

  Plasma concentrations of protease inhibitors increase with age, investigators from the United Kingdom report in the Journal of Antimicrobial Chemotherapy. Each ten-year increment in age was associated with a significant increase in concentrations of protease inhibitors in plasma. In contrast, there ...

  05 April 2013 | Michael Carter

• Dosing of key TB drug rifampicin could go higher

  Rifampicin, a key drug in tuberculosis (TB) treatment, can be tolerated at much higher doses than used in current clinical practice – suggesting that much higher drug levels may lead to a more rapid treatment response, allowing the treatment ...

  07 March 2013 | Keith Alcorn

• Combined oral contraception has less effect on nevirapine than efavirenz levels

  HIV therapy based on efavirenz may less suitable for women taking combined oral contraception due to greater reductions in efavirenz levels and a higher frequency of hormonal contraception side effects, according to research conducted in Thailand and ...

  21 December 2012 | Michael Carter

• CNS symptoms common in people taking raltegravir

  Approximately 10% of patients taking the antiretroviral drug raltegravir (Isentress) develop central nervous system (CNS) side-effects, research published in the online edition of AIDS shows. The development of CNS side-effects was associated with the co-administration of tenofovir (Viread, also in Truvada, ...

  10 October 2012 | Michael Carter

• Raltegravir 800mg twice daily appears a good alternative to efavirenz for HIV-TB treatment

  Raltegravir seems to be a suitable alternative to efavirenz for HIV-TB co-infected patients while receiving TB treatment, according to 24-week results of the ANRS 12 180 REFLATE study presented at the Nineteenth International AIDS Conference (AIDS 2012) in Washington ...

  31 July 2012 | Lesley Odendal

• Cobicistat matches ritonavir as atazanavir booster

  The new boosting agent cobicistat works as well as ritonavir (Norvir) as a pharmaco-enhancer or booster for the first-line protease inhibitor atazanavir (Reyataz) at 48 weeks, according to a report presented last week at the 19th International AIDS Conference in ...

  30 July 2012 | Liz Highleyman

• Co-administration of rifampicin and efavirenz does not reduce efavirenz concentrations or efficacy

  Standard dosing of efavirenz, that was not adjusted for patient weight, resulted in therapeutic efavirenz concentrations and excellent virological outcomes in patients coinfected with TB and HIV who were also taking a rifampicin-containing TB treatment, according to results from the ...

  24 July 2012 | Lesley Odendal

• No evidence of an interaction between abacavir and ribavirin

  There is no evidence of an interaction between the anti-HIV drug abacavir and the anti-hepatitis C agent ribavirin, investigators report in the online edition of AIDS. Some earlier research reported poorer hepatitis C treatment outcomes in co-infected patients whose antiretroviral regimens ...

  17 July 2012 | Michael Carter

• Study shows that use of darunavir/ritonavir and etravirine in HIV treatment as a prevention method is biologically plausible

  A pharmacokinetic study suggests that ritonavir-boosted darunavir (Prezista) and etravirine (Intelence) achieve high concentrations in semen and rectal tissue, and could therefore help avert HIV transmission and infection, especially in gay men. Concentrations of these antiretrovirals were monitored over an eight-day ...

  13 June 2012 | Michael Carter

• Studies look at interactions between new hepatitis C drugs and HIV antiretrovirals

  Drug-drug interactions between direct-acting antiviral agents for hepatitis C and some antiretroviral medications used to treat HIV are common, but are often modest and can be managed with dose adjustments when treating people with HIV/HCV coinfection, researchers reported at ...

  14 March 2012 | Liz Highleyman

More news

Drug interactions and pharmacokinetics news selected from other sources

• Nanoparticles May Transport HIV Meds to the Brain

  Researchers have had early success in a method that might one day thwart the powerful blood-brain barrier and effectively deliver antiretrovirals to the brain.

  16 May 2013 | AIDSMeds

• Protease Inhibitors Boost Levels of Cenicriviroc, a CCR5/CCR2 Antagonist

  Ritonavir, darunavir/ritonavir, and atazanavir/ritonavir all more than tripled exposure of cenicriviroc, an investigational CCR5 and CCR2 receptor antagonist, in 60 healthy volunteers. There were no serious or unexpected adverse events in these 20-day studies.

  14 May 2013 | NATAP

• Changes to label for Atripla tablets

  FDA recently approved changes to the Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablet label to include the following changes: Lists Stribild as one of the drugs that should not be coadministered with Atripla; Adds drug interaction information for raltegravir, boceprevir and telaprevir.

  18 April 2013 | FDA

• Prezista (darunavir) label change - drug interaction information

  The FDA recently approved changes to the Prezista (darunavir) label to reflect drug interaction information with artemether/lumefantrine. The specific changes are outlined below.

  02 March 2013 | US Food and Drug Administration

• Updated HIV Treatment Guidelines Include Stronger Recommendation for Acute Infection

  Among the key changes are additional information about the most recently approved antiretroviral agents and a recommendation that newly infected people with HIV should be offered combination ART. The guidelines continue to recommend treatment for all people with HIV, both to reduce the risk of disease progressionand for the prevention of HIV transmission.

  15 February 2013 | HIVandHepatitis.com

• Copy of Drug interaction warning for hepatitis C: serious side effects when using telaprevir and bosentan

  A medical team in Paris, France, has reported an unexpected and disturbing drug interaction between a drug used to treat pulmonary arterial hypertension—bosentan (Tracleer)—and the HCV drug telaprevir. The interaction led to serious side effects.

  15 February 2013 | CATIE

• Drug interaction warning for hepatitis C: serious side effects when using telaprevir and bosentan

  A medical team in Paris, France, has reported an unexpected and disturbing drug interaction between a drug used to treat pulmonary arterial hypertension—bosentan (Tracleer)—and the HCV drug telaprevir. The interaction led to serious side effects.

  15 February 2013 | CATIE

• Updated U.S. DHHS guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents

  New recommendations on drug-resistance testing, genotypic tropism assays, starting treatment, acute infection, pregnancy and interactions.

  15 February 2013 | AIDSinfo

• Certain Meds Mixed With Grapefruit Juice Can Be a Fatal Cocktail

  The scientist who discovered that grapefruit can alter  drug levels in the body has released an updated list of 85 medications that may cause such reactions, in order to reflect releases of new medications over the past four years.

  21 December 2012 | AIDSMeds

• Mistakes are still commonly made in prescriptions of antiretroviral medications

  Research presented at IDWeek 2012- concludes that despite advances in electronic medical records, mistakes are still commonly made in the prescription of antiretroviral medications for hospitalized HIV-positive patients. At the same time, a trio of studies suggests however, that electronic records in combination with increased clinical education can help to greatly decrease medical errors.

  22 October 2012 | News Medical

More news